Management of Hyperammonemia and Hepatic Encephalopathy in Cirrhosis

First‑Line Therapy with Lactulose

• Lactulose is recommended as the primary treatment for elevated ammonia (≈ 98 µg/dL) and the onset of hepatic encephalopathy in patients with cirrhosis.  [Clinical practice guideline, 2020] 1
• Initiate lactulose orally at 20–30 g (≈ 30–45 mL) every 1–2 hours until the patient achieves ≥ 2 bowel movements per day; then titrate to maintain 2–3 soft stools daily. 1
• Mechanistically, lactulose is metabolized by colonic bacteria to acids that lower colonic pH, converting absorbable ammonia (NH₃) to non‑absorbable ammonium (NH₄⁺) which is trapped in the lumen and eliminated in stool. 1
• Meta‑analysis data show an overall clinical response rate of 82.5 % to lactulose‑based regimens, with a relative risk of symptom improvement of 0.62 (95 % CI 0.46–0.84) compared with placebo. [Level A evidence] 1

When to Add Rifaximin

• Add rifaximin (550 mg twice daily or 400 mg three times daily) in patients with recurrent hepatic encephalopathy episodes or inadequate response to lactulose alone. [1][2]
• Combination therapy (lactulose + rifaximin) yields 76 % recovery within 10 days versus 44 % with lactulose alone (P = 0.004) and shortens hospital stay (5.8 days vs 8.2 days, P = 0.001). [Level B evidence] [1][2]

Alternative Routes of Lactulose Administration

• For patients unable to take oral medication or with severe encephalopathy (West‑Haven grade 3–4), administer lactulose enema: 300 mL lactulose mixed with 700 mL water (total 1 L), given 3–4 times daily; retain the solution for at least 30 minutes. 1
• Nasogastric tube delivery of lactulose is an option when the airway is protected but oral intake is not possible. 1

Adjunctive Therapies for Refractory Cases

• IV LOLA is considered when patients fail to improve with lactulose ± rifaximin. [1][2]
• BCAA supplementation may be added as an ancillary option in cirrhotic patients with sarcopenia. [1][3]

Agents Not Recommended

• Neomycin and metronidazole are discouraged because of significant adverse‑effect profiles (neomycin: intestinal malabsorption, nephro‑ and ototoxicity; metronidazole: peripheral neuropathy). [1][3]

Treatment of Hepatic Encephalopathy

First-Line Therapy

• The American Association for the Study of Liver Diseases recommends lactulose as the first-line medication for treating hepatic encephalopathy and elevated ammonia levels, dosed at 25 mL orally every 1-2 hours initially until producing 2-3 soft bowel movements daily, then titrated to maintain this frequency 4, 5
• Lactulose should be initiated immediately as the primary treatment for overt hepatic encephalopathy, with an initial dosing strategy of 25 mL of lactulose syrup every 1-2 hours until achieving at least 2 soft or loose bowel movements per day 4, 6
• Maintenance dosing of lactulose should be titrated to maintain 2-3 bowel movements daily 4, 5

Add-On Therapy

• Rifaximin 550 mg twice daily should be added to lactulose for prevention of recurrent hepatic encephalopathy episodes, with evidence showing superiority of rifaximin versus placebo when 91% of patients were concurrently using lactulose 4, 5
• The European Association for the Study of the Liver recommends rifaximin as an add-on therapy to lactulose for the prevention of recurrent hepatic encephalopathy episodes 5

Alternative and Adjunctive Therapies

• Intravenous L-Ornithine L-Aspartate (LOLA) 30 g/day can be considered for persistent or severe hepatic encephalopathy, in combination with lactulose, leading to lower grade of hepatic encephalopathy within 1-4 days compared to lactulose alone 7, 5, 8
• Oral Branched-Chain Amino Acids (BCAAs) can be used as an alternative or additional agent for patients not responding to conventional therapy, with meta-analysis of 8 RCTs showing improvement in manifestations of episodic hepatic encephalopathy 5, 8

Special Considerations

• Polyethylene glycol may provide more rapid improvement when combined with lactulose, but requires further validation 4, 8
• Neomycin should be avoided for long-term use due to ototoxicity, nephrotoxicity, and neurotoxicity 4, 6